Evaluation of irisin, retinol-binding protein 4, and leptin serum levels as biomarkers of macrovascular complications involvement in Saudi type 2 diabetes mellitus. A case-control study

References

1. ↵
   1. Lovic D,
   2. Piperidou A,
   3. Zografou I,
   4. Grassos H,
   5. Pittaras A,
   6. Manolis A

   (2020) The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol 18:104–109.

   OpenUrl
2. ↵
   1. Hegazy GA,
   2. Awan Z,
   3. Hashem E,
   4. Al-Ama N,
   5. Abunaji AB

   (2019) Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications. J Int Med Res 1:1–11.

   OpenUrl
3. ↵
   1. Price AH,
   2. Weir CJ,
   3. Welsh P,
   4. McLachlan S,
   5. Strachan MWJ,
   6. Sattar N,
   7. et al.

   (2017) Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: The Edinburgh type 2 diabetes study. Atherosclerosis 264:67–73.

   OpenUrl
4. ↵
   1. Anastasilakis AD,
   2. Koulaxis D,
   3. Kefala N,
   4. Polyzos SA,
   5. Upadhyay J,
   6. Pagkalidou E,
   7. et al.

   (2017) Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism 73:1–8.

   OpenUrl
5. ↵
   1. Lamiquiz-Moneo I,
   2. Bea AM,
   3. Palacios-Pérez C,
   4. De Miguel-Etayo P,
   5. González-Gil EM,
   6. López-Ariño C,
   7. et al.

   (2020) Effect of lifestyle intervention in the concentration of adipoquines and branched chain amino acids in subjects with high risk of developing type 2 diabetes: Feel4Diabetes Study. Cells 9:693.

   OpenUrl
6. ↵
   1. Wessel H,
   2. Saeed A,
   3. Heegsma J,
   4. Connelly MA,
   5. Faber KN,
   6. Dullaart RP

   (2019) Plasma levels of retinol binding protein 4 relate to large VLDL and small LDL particles in subjects with and without type 2 diabetes. J Clin Med 8:1792.

   OpenUrl
7. ↵
   1. Al Sheikh MH

   (2017) The determinants of leptin levels in diabetic and nondiabetic Saudi Males. Int J Endocrinol 2017, 3506871.
8. ↵
   1. Zhang M,
   2. Chen P,
   3. Chen S,
   4. Sun Q,
   5. Zeng QC,
   6. Chen JY,
   7. et al.

   (2014) The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci 18:1567–1572.

   OpenUrlPubMed
9. ↵
   1. Stanford KI,
   2. Goodyear LJ

   (2018) Muscle-adipose tissue cross talk. Cold Spring Harb Perspect Med 8:a029801.

   OpenUrlAbstract/FREE Full Text
10. ↵
    1. Matsuo Y,
    2. Gleitsmann K,
    3. Mangner N,
    4. et al.

    (2015) Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines. J Cachexia Sarcopenia Muscle 6:62–72.

    OpenUrl
11. ↵
    1. Kadoglou NP,
    2. Lambadiari V,
    3. Gastounioti A,
    4. Gkekas C,
    5. Giannakopoulos TG,
    6. Koulia K,
    7. et al.

    (2014) The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability. Atherosclerosis 235:606–612.

    OpenUrlCrossRefPubMed
12. ↵
    1. Kwanbunjan K,
    2. Panprathip P,
    3. Phosat C,
    4. et al.

    (2018) Association of retinol binding protein 4 and transthyretin with triglyceride levels and insulin resistance in rural thais with high type 2 diabetes risk. BMC Endocr Disord 18:26.

    OpenUrlCrossRefPubMed
13. ↵
    1. Memon AG,
    2. Rahman MA,
    3. Alghasham A,
    4. Hamid S,
    5. Hamid Q

    (2015) Correlation between adipocytokines and AGE products in diabetic and non-diabetic patients with myocardial infarction. Res Chem Intermed 41:1625–1634.

    OpenUrl